# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹19,005 Mn** Q1 FY26 (-8% YoY, +7% QoQ) (3-year CAGR: 7%) * **Gross Margin:** **57%** Q1 FY26 (+700 bps YoY) · **Guided FY26: 50–52%** * **EBITDA Margin:** **27.5%** Q1 FY26 (resilient) · **Guided FY26: 25–27%** * **Balance Sheet:** **₹1,06,003 Mn** net worth · **₹41,554 Mn** net cash * **Working Capital:** **91 days** trade working capital (vs. 73 days in Mar-25) ## B. Revenue Growth * **Mixed Top-Line Trend:** Revenue decline attributed to a high base effect from prior-year strength, though sequential improvement signals **recovery momentum**. ## C. Gross Margin * **Outperformance with Caveats:** Gross margin significantly exceeded guidance on **favorable product mix** and cost actions, but management expects **quarterly volatility** and maintains full-year margin guidance. * **Pharma Margin Clarity:** Reported pharma gross margin of 52% reflects reclassification; on a comparable basis, margins show **modest year-on-year compression** from 55% to 52%. ## D. EBITDA Margin * **Pharma Segment Path to Profitability:** Elevated overheads reflect strategic R&D investment, with **break-even EBITDA expected within 12–18 months**. ## E. Balance Sheet * **Strong Financial Position:** Balance sheet remains robust with high net worth and **significant net cash**, supporting strategic flexibility. * **Working Capital Pressure:** Increase in trade working capital to 91 days driven by factors beyond inventory, though domestic receivables remain stable and **no credit concerns** noted. --- # 2. Segment & Product Performance ## A. Key Figures * **CSM Revenue Growth:** **6%** domestic YoY (Q1 FY26) * **Pharma Revenue Growth:** **186%** YoY (Q1 FY26) * **New Product Growth:** **46%** YoY (specialty chemicals, last 3 years) * **Biologicals Contribution:** ~**20%** of domestic revenue * **Jivagro Revenue Share:** **17–20%** of domestic revenue ## B. CSM Business * **Resilient Core Growth:** Domestic CSM delivered solid growth despite a **temporary regulatory setback in biologicals**, with momentum sustained by advanced product mix and Kharif season tailwinds. * **Innovation Acceleration:** Product pipeline significantly de-risked with **over 20 new products** in development and **8 to 10 launches planned for FY26**, signaling increased R&D commercialization velocity. * **Strategic Expansion:** Company is actively evaluating **inorganic opportunities in India** across segments, supporting its transition from agri-sciences to a diversified lifesciences player with global growth engines. * **Supply Dynamics Normalizing:** Recent **volume decline attributed to customer inventory adjustments**, not contract losses, with resumption of normal supply expected in H2. ## C. Pharma Revenue * **Explosive CRDMO-Led Growth:** Pharma segment achieved near-tripling of revenue on the back of **strong CRDMO platform traction**, driven by API sales and development services with biotech and big pharma partners. * **Client Onboarding Momentum:** **Two major pharma clients already onboarded**, with **3 to 4 total expected by year-end**, laying foundation for durable growth amid biotech funding headwinds. * **Scalable Molecule Pipeline:** **15 molecules commercialized over past 3 years**, with **select high-impact assets poised for outsized contribution in next 3–4 years**, underpinning long-term visibility. ## D. Biologicals Impact * **Near-Term Headwind, Long-Term Upside:** Biologicals segment currently idle domestically due to **regulatory pause**, but acquired global business is on track and expected to deliver **superior margins in 4–5 years** post-development cycle. * **Strategic Confidence:** Despite current disruption, management reaffirms biologicals as a future margin leader, with innovative pipeline in development. ## E. Specialty Chemicals * **High-Growth Specialty Segments:** Electronic and specialty chemicals gaining scale, with **10+ active projects** and **five to seven developed products** attracting global customer traction. * **Jivagro Transformation:** Former generics portfolio now repositioned as a **specialty horticulture-focused division**, contributing meaningfully to domestic revenue. * **Plant Health & Electronics Outlook:** **$8–10M annual revenue** from Plant Health Care, while electronic chemicals expected to become a **major business within 4–5 years**. --- # 3. Order Book & Demand ## A. Key Figures * **Order Book:** **$1.2 billion** ## B. Export Schedules * **Receivables Build from Export Growth:** Increase in receivables aligned with planned export operations, indicating healthy order execution. ## C. Domestic Demand * **Challenging Global Macro Backdrop:** AgChem industry recovery delayed by two years of weak commodity prices, farm income pressures, and geopolitical uncertainties. * **Resilient Domestic Fundamentals:** Favorable monsoons and strong sowing supported local demand, though growth was tempered by regulatory headwinds in biologicals and fertilizer supply gaps. * **Innovation Driving Export Freshness:** Recent product launches underpin a meaningful share of exports, reflecting robust innovation pipeline and market uptake. * **Growth Recovery Pathway:** Return to double-digit expansion hinges on sustained customer re-engagement and normalization of global supply chains. ## D. New Molecule Launches * **Strategic Product Expansion:** Launch of PIOXANILIPROLE targets high-value pest control in key row crops and vegetables, broadening market reach. ## E. CRDMO Pipeline * **Positive Industry Tailwinds:** Gradual destocking and accelerated **China Plus One** adoption boost outsourcing demand and supply chain diversification. * **Rising Focus on Biologicals & Partnerships:** Climate-driven demand for biologicals and strategic value-chain collaborations enhance resilience and cost efficiency. * **Pipeline Momentum:** CRDMO progress marked by late-stage program development and customer base expansion, powered by differentiated technologies like **flow chemistry**. --- # 4. Capacity & Manufacturing ## A. Key Figures * **CAPEX Guidance:** **₹700–800 Cr** (FY26) * **Tax Rate Guidance:** **22–23%** (FY26) ## B. Plant Expansion * **Phased Capacity Addition:** One of two new manufacturing plants (MPPs) to commence operations in Q4 of current year, with the second expected in early next fiscal year. ## C. CAPEX Plan * **Strategic Growth Investments:** CAPEX focused on scaling acquired businesses, advancing CSM export capabilities, and enhancing distribution through technology. * **Operational Transformation:** Business process reengineering underway via **S4 HANA** and global supply chain integration to drive synergies. * **Innovation & Diversification:** Investments support growth in PIHS, PHC, and Discovery R&D; early-stage progress in electronic chemicals and semiconductors diversification noted. ## D. Production Ramp-Up * **Multi-Year Ramp-Up Trajectory:** Full production scale expected over a **3–4 year** horizon, indicating long-term capacity absorption. --- # 5. R&D & Innovation ## A. Discovery Molecules * **Long-Term Growth Drivers:** Structural tailwinds from **shrinking arable land**, **climate volatility**, and **rising food demand** are accelerating adoption of AI-driven research and precision farming solutions. * **Biologicals Expansion:** R&D in biologicals is being scaled with targeted focus on **B. S., Brazil, Mexico, and India**, supported by strategic partnerships to enhance market access and innovation speed. * **PIOXANILIPROLE Progress:** Advanced development stage achieved with **positive Phase III results**; regulatory filing submitted in India, marking a key milestone toward potential **global launch in ~5 years** via partnership model. * **Global Commercialization Push:** Active advanced discussions with distribution partners worldwide, leveraging **India-based R&D capabilities** to enable cost-effective, near-home support for international rollouts. * **New Discovery Milestone:** Filed first proprietary discovery molecule in **Lepidopteran insecticides**, targeting a **multi-thousand-crore domestic market**, signaling growing innovation depth despite lack of near-term financial visibility. ## B. Product Pipeline * **Strategic Biologicals Scale-Up:** Acquisition of **Plant Health Care** bolsters global biologicals platform, adding proven **PREtec and Harpin technologies** that enhance crop resilience and yield sustainably. * **PIOXANILIPROLE Regulatory Milestone:** Registration filed for **India’s first indigenous discovery** in its class, underscoring R&D maturity and long-term pipeline ambition. * **Multi-Market Development:** PIOXANILIPROLE is under active evaluation across **key geographies and crops**, indicating broad commercial potential beyond initial launch plans. --- # 6. Regulatory & Supply Risks ## A. Biologicals Ban * **Headline:** Regulatory resolution for key product pyro in Brazil expected within ~1 month, with court proceedings progressing positively. * **Headline:** Operations anticipated to resume post-resolution; sector importance underscored by high-level government support for agricultural biologicals. * **Headline:** Domestic biologicals sales normalization in India remains under government and court purview, with no immediate resolution in sight. ## B. U.S. Tariff Uncertainty * **Headline:** No current U.S. tariff impact on key products, and no immediate challenges expected despite ongoing policy uncertainty. * **Headline:** A stabilized U.S. tariff environment could unlock future market opportunities, amid strong global tailwinds from **China Plus One** supply chain diversification. ## C. Supply Chain Delays * **Headline:** Rising trade receivables driven by industry-wide inventory buildup and **fertilizer shortages**, leading to delayed agrochemical collections. * **Headline:** Sales quality remains robust, with **no expected increase in sales returns** versus prior year despite collection delays. --- # 7. Guidance & Outlook ## A. Key Figures * **FY26 Revenue Guidance:** **Middle single-digit growth** (vs. prior 75% pharma segment target) * **Pharma CRDMO Target:** **2–3x current revenue** in 3–4 years * **H2 Growth Requirement:** **9%-10% growth** needed in remainder of FY26 ## B. FY26 Revenue View * **Pharma Growth Ambition:** Leadership reaffirms aggressive **75% revenue growth target for pharma business by FY26**, underpinned by innovation and partnerships. * **Near-Term Headwinds:** Q1 softness attributed to inventory balancing and **domestic regulatory delays**, creating execution risk to full-year guidance. * **Segment Resilience:** CSM segment provides stability via **firm supply schedules**, supporting confidence in second-half rebound. ## C. H2 Acceleration * **H2-Weighted Trajectory:** Q1 performance in line with plan; AgChem export decline reflects **intentional customer inventory adjustments**, not demand erosion. * **Macro Caution:**